Genprex Stock Drops 9.5% After Congressman Moore Buys $1,000–$15,000 Stake
Genprex shares fell 9.5% after Congressman Tim Moore purchased $1,001 to $15,000 in stock on Feb. 5, marking his fourth acquisition in the gene therapy company. GNPX has a market capitalization of $5.2 million after Moore allocated roughly $31,000 to $115,000 across three 2025 purchases.
1. Moore’s Recent Purchase of Genprex
On Feb. 5, Congressman Tim Moore acquired between $1,001 and $15,000 of Genprex stock, marking his fourth purchase of the small gene therapy company. The transaction coincided with a 9.46% decline in GNPX shares, making it one of the session’s weakest performers.
2. Genprex Market Capitalization and Past Buys
Genprex now carries a market capitalization of $5.2 million following Moore’s investments, which included three separate buys in 2025 totaling between $31,000 and $115,000. The pattern of recurring insider purchases underscores growing attention on the company’s development pipeline despite its modest valuation.